R
Robin Millman
Researcher at University College London
Publications - 29
Citations - 4797
Robin Millman is an academic researcher from University College London. The author has contributed to research in topics: Prostate cancer & Docetaxel. The author has an hindex of 12, co-authored 20 publications receiving 3388 citations.
Papers
More filters
Journal ArticleDOI
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James,Nicholas D. James,Matthew R. Sydes,Noel W. Clarke,Malcolm David Mason,David P. Dearnaley,Melissa R. Spears,Alastair W. S. Ritchie,Chris Parker,J. Martin Russell,Gerhardt Attard,Johann S. de Bono,William Cross,Robert Jones,George N. Thalmann,Claire Amos,David Matheson,Robin Millman,Mymoona Alzouebi,Sharon Beesley,Alison Birtle,Susannah Brock,Richard Cathomas,Prabir Chakraborti,Simon Chowdhury,Audrey Cook,Tony Elliott,Joanna Gale,Stephanie Gibbs,John Graham,J. Hetherington,Robert Hughes,Robert W. Laing,Fiona McKinna,Duncan McLaren,Joe M. O'Sullivan,Omi Parikh,Clive Peedell,Andrew Protheroe,Angus Robinson,Narayanan Srihari,Rajaguru Srinivasan,John Staffurth,Santhanam Sundar,Shaun Tolan,David Tsang,John Wagstaff,Mahesh K.B. Parmar +47 more
TL;DR: Zoledronic acid showed no evidence of survival improvement and should not be part of standard of care for this population of men, and heterogeneity in treatment effect across prespecified subsets was not found.
Journal ArticleDOI
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Nicholas D. James,Johann S. de Bono,Melissa R. Spears,Noel W. Clarke,Malcolm David Mason,David P. Dearnaley,Alastair W. S. Ritchie,Claire Amos,Clare Gilson,Robert Jones,David Matheson,Robin Millman,Gerhardt Attard,Simon Chowdhury,William Cross,Silke Gillessen,Chris Parker,J. Martin Russell,Dominik Berthold,Chris Brawley,Fawzi Adab,San Aung,Alison Birtle,Jo Bowen,Susannah Brock,Prabir Chakraborti,C.L. Ferguson,Joanna Gale,Emma Gray,Mohan Hingorani,Peter Hoskin,Jason F. Lester,Zafar Malik,Fiona McKinna,Neil McPhail,Julian Money-Kyrle,Joe M. O'Sullivan,Omi Parikh,Andrew Protheroe,Angus Robinson,Narayanan Srihari,Carys Thomas,John Wagstaff,James D. Wylie,Anjali Zarkar,Mahesh K.B. Parmar,Matthew R. Sydes +46 more
TL;DR: Among men with locally advanced or metastatic prostate cancer, ADT plus abiraterone and prednisolone was associated with significantly higher rates of overall and failure‐free survival than ADT alone.
Journal ArticleDOI
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Chris Parker,Nicholas D. James,Christopher D. Brawley,Noel W. Clarke,Alex Hoyle,Adnan Ali,A.W.S. Ritchie,Gerhardt Attard,Simon Chowdhury,William Cross,David P. Dearnaley,Silke Gillessen,Silke Gillessen,Clare Gilson,Robert Jones,Ruth E Langley,Zafar Malik,Malcolm David Mason,David Matheson,Robin Millman,J. Martin Russell,George N. Thalmann,Claire Amos,Roberto Alonzi,Amit Bahl,Alison Birtle,O.S. Din,Hassan Douis,C. Eswar,Joanna Gale,Melissa Gannon,Sai Jonnada,S. Khaksar,Jason F. Lester,Joe M. O'Sullivan,Omi Parikh,Ian Pedley,Delia Pudney,D. Sheehan,Narayanan Srihari,Anna T.H. Tran,Mahesh K.B. Parmar,Matthew R. Sydes +42 more
TL;DR: Radiotherapy to the prostate did not improve overall survival for unselected patients with newly diagnosed metastatic prostate cancer, and the benefit would be greatest in patients with a low metastatic burden.
Journal ArticleDOI
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]
Silke Gillessen,Gerhardt Attard,Tomasz M. Beer,Himisha Beltran,Anders Bjartell,Alberto Bossi,Alberto Briganti,Robert G. Bristow,Kim N. Chi,Noel W. Clarke,Ian D. Davis,Johann S. de Bono,Charles G. Drake,Ignacio Duran,Ros Eeles,Eleni Efstathiou,Christopher P. Evans,Stefano Fanti,Felix Y. Feng,Karim Fizazi,Mark Frydenberg,Martin E. Gleave,Susan Halabi,Axel Heidenreich,Axel Heidenreich,Daniel Heinrich,Celestia S. Higano,Celestia S. Higano,Michael S Hofman,Michael S Hofman,Maha Hussain,Nicolas James,Ravindran Kanesvaran,Philip W. Kantoff,Philip W. Kantoff,Raja B. Khauli,Raya Leibowitz,Chris Logothetis,Chris Logothetis,Fernando C. Maluf,Robin Millman,Alicia K. Morgans,Michael J. Morris,Nicolas Mottet,Hind Mrabti,Declan G. Murphy,Declan G. Murphy,Vedang Murthy,William Oh,Piet Ost,Joe M. O'Sullivan,Joe M. O'Sullivan,Anwar R. Padhani,Chris Parker,Darren M.C. Poon,Colin C. Pritchard,Robert E. Reiter,Mack Roach,Mark A. Rubin,Charles J. Ryan,Fred Saad,Juan Pablo Sade,Oliver Sartor,Howard I. Scher,Howard I. Scher,Neal D. Shore,Eric J. Small,Matthew R. Smith,Howard R. Soule,Cora N. Sternberg,Thomas Steuber,Hiroyoshi Suzuki,Christopher Sweeney,Matthew R. Sydes,Mary-Ellen Taplin,Bertrand Tombal,Levent Türkeri,Inge M. van Oort,Almudena Zapatero,Aurelius Omlin,Aurelius Omlin +80 more
TL;DR: These voting results from a panel of prostate cancer experts can help clinicians and patients navigate controversial areas of advanced prostate management for which high-level evidence is sparse and provide a practical guide to help clinicians discuss therapeutic options with patients.
Journal ArticleDOI
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
Noel W. Clarke,Adnan Ali,F.C. Ingleby,Alex Hoyle,Claire Amos,Gerhardt Attard,Christopher D. Brawley,J. Calvert,Simon Chowdhury,Adrian Cook,William Cross,David P. Dearnaley,Hassan Douis,Duncan C. Gilbert,Silke Gillessen,Robert Jones,Ruth E Langley,Archie Macnair,Zafar Malik,Malcolm David Mason,David Matheson,Robin Millman,Chris Parker,A.W.S. Ritchie,H. Rush,J.M. Russell,Janet E. Brown,Sharon Beesley,Alison Birtle,L. Capaldi,Joanna Gale,Stephanie Gibbs,Anna Lydon,A. Nikapota,Aurelius Omlin,Joe M O'Sullivan,Omi Parikh,Andrew Protheroe,S. Rudman,Narayanan Srihari,Matthew S. Simms,Jacob Tanguay,Shaun Tolan,John Wagstaff,Jan Wallace,James D. Wylie,Anjali Zarkar,Matthew R. Sydes,Mona Parmar,Nicholas D. James +49 more
TL;DR: The clinically significant benefit in survival for upfront docetaxel persists at longer follow-up, with no evidence that benefit differed by metastatic burden.